Tesamorelin Improves Brain Function in HIV Patients with Abdominal Obesity
Background
Persons living with HIV (PLWH) often experience neurocognitive impairment (NCI), a spectrum of cognitive difficulties ranging from mild to severe, impacting daily life and quality of life. This impairment is frequently exacerbated by comorbidities like abdominal obesity, which is prevalent in PLWH due to long-term antiretroviral therapy and metabolic changes. While Tesamorelin is known to reduce visceral adipose tissue (VAT) in PLWH, its potential to mitigate neurocognitive impairment in this specific population with abdominal obesity has been largely unexplored.
Results
The study found that Tesamorelin significantly improved global neurocognitive performance compared to placebo. Participants receiving Tesamorelin showed a 15% increase in their global neurocognitive composite score from baseline, whereas the placebo group saw only a 2% increase (p<0.01). Specific cognitive domains also benefited, with verbal learning scores improving by 20% in the Tesamorelin group (p=0.005). This cognitive improvement was accompanied by a substantial reduction in visceral fat. > The Tesamorelin group experienced an 18% reduction in visceral adipose tissue (VAT) compared to a 2% increase in the placebo group (p<0.001), suggesting a potential link between metabolic improvement and brain health. Furthermore, Tesamorelin was well-tolerated, with adverse events comparable to placebo, except for a slightly higher incidence of mild injection site reactions (5% vs. 1%).
Why It Matters
These findings are highly significant, as they suggest that Tesamorelin, a growth hormone-releasing hormone (GHRH) analog, could offer a novel therapeutic strategy for a debilitating comorbidity in PLWH. The dual benefit of reducing abdominal obesity and improving neurocognitive function addresses two major health challenges simultaneously. This study provides strong evidence supporting the potential for Tesamorelin to be repurposed or expanded for clinical use in managing HIV-associated neurocognitive impairment. Future research should focus on larger, longer-term Phase III human trials to confirm these benefits and explore the underlying mechanisms linking VAT reduction to cognitive improvement.